Rankings
▼
Calendar
TELO Q3 2022 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$233,497
Net Income
-$233,497
EPS (Diluted)
$-0.01
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$82,395
Free Cash Flow
-$82,395
Stock-Based Comp.
$0
← FY 2022
All Quarters
Q4 2022 →
